CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.
The collaboration allows for seamless integration of patient-specific results from Biotheranostics’ biomarkers that provide molecular profiles for patients with early stage breast cancer and metastatic cancer into the Syapse Precision Medicine Platform. The platform is used by health systems and cancer care networks to provide decision support to clinicians in the care of cancer patients and enable health systems to make precision medicine a routine part of cancer care.
Biotheranostics, 877-886-6739
Syapse, 650-924-1461